Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms.
Here we report on thrombolytic and hypotensive actions of Xanthinol nicotinate (Sadamin) in rats and on its anti-platelet and fibrinolytic effects in patients with peripheral arterial obliterative disease (PAOD). Special consideration was given to a proposal of new mechanisms of anti-platelet and thrombolytic actions of Sadamin. We conclude that the mechanism of anti-platelet and thrombolytic activity of Sadamin partly consists of a simultaneous release of endogenous prostacyclin and nitric oxide by the nicotinate component of Sadamin, whereas the theophylline component is responsible for enhancement of physiological actions of these endothelial mediators at the level of cyclic nucleotides which are their second messengers.
Jagiellonian University Medical School, Cracow, Poland.
K
K
Bieroń
J
J
Swies
E
E
Kostka-Trabka
R J
RJ
Gryglewski
D000328:Adult; D000368:Aged; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014665:Vasodilator Agents / Q000494:pharmacology*; D014971:Xanthinol Niacinate / Q000494:pharmacology*
D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D014971:Xanthinol Niacinate